bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 4,000 shares of bluebird bio stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $202.36, for a total value of $809,440.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
David Davidson also recently made the following trade(s):
- On Monday, January 8th, David Davidson sold 3,522 shares of bluebird bio stock. The stock was sold at an average price of $173.61, for a total value of $611,454.42.
- On Wednesday, January 3rd, David Davidson sold 6,000 shares of bluebird bio stock. The stock was sold at an average price of $180.30, for a total value of $1,081,800.00.
bluebird bio Inc (BLUE) traded up $5.70 during midday trading on Monday, reaching $197.50. The company’s stock had a trading volume of 560,424 shares, compared to its average volume of 945,062. The firm has a market capitalization of $9,050.00, a P/E ratio of -28.17 and a beta of 2.07. bluebird bio Inc has a 12 month low of $73.95 and a 12 month high of $222.03.
BLUE has been the topic of a number of recent analyst reports. Wedbush reiterated an “outperform” rating and issued a $174.00 price objective (up from $135.00) on shares of bluebird bio in a research note on Thursday, November 2nd. Evercore ISI upgraded bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price objective on the stock in a research note on Monday, October 16th. BMO Capital Markets lifted their price objective on bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a research note on Monday, October 30th. Maxim Group set a $170.00 price objective on bluebird bio and gave the stock a “buy” rating in a research note on Friday, November 17th. Finally, BidaskClub lowered bluebird bio from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $161.45.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. boosted its holdings in bluebird bio by 2,110.3% during the fourth quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 612 shares in the last quarter. QS Investors LLC boosted its holdings in shares of bluebird bio by 70.7% in the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 500 shares in the last quarter. NuWave Investment Management LLC acquired a new position in shares of bluebird bio in the 4th quarter worth approximately $135,000. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of bluebird bio by 454.2% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 813 shares in the last quarter. Finally, Biondo Investment Advisors LLC acquired a new position in shares of bluebird bio in the 3rd quarter worth approximately $203,000.
TRADEMARK VIOLATION NOTICE: “David Davidson Sells 4,000 Shares of bluebird bio Inc (NASDAQ:BLUE) Stock” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/12/david-davidson-sells-4000-shares-of-bluebird-bio-inc-blue-stock.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.